This “Seborrhea - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Seborrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Seborrhea Understanding
Seborrheic dermatitis is a common skin disease that causes an itchy rash with flaky scales. It causes redness on light skin and light patches on darker skin. It's also called dandruff, cradle cap, seborrhea, seborrheic eczema, and seborrheic psoriasis. Seborrhea often affects the scalp. Other sites include the face, ears, eyebrows and eyelids, umbilicus, and genitalia. Primary seborrhea is inherited and Secondary seborrhea is more common; however the exact cause cannot always be determined.It is likely that a number of factors, such as hormones and stress, can cause it. A yeast-like organism plays an important role. Infants may get seborrhea. Seborrhea also affects adults and elderly persons, and is more common in men than in women. Seborrhea occurs more frequently in persons with oily skin. Medical history and the complete examination of the skin may help in the diagnosis. Seborrheic dermatitis will sometimes clear up by itself. But often, it's a lifelong issue that clears and flares.
"Seborrhea - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Seborrhea pipeline landscape is provided which includes the disease overview and Seborrhea treatment guidelines. The assessment part of the report embraces, in depth Seborrhea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Seborrhea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Seborrhea R&D. The therapies under development are focused on novel approaches to treat/improve Seborrhea.
This segment of the Seborrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Roflumilast foam is a once-daily topical foam formulation of a highly potent and selective PDE4 inhibitor that Arcutis is developing particularly to treat inflammatory dermatoses in hair-bearing areas of the body such as the scalp, although it is usable in all areas of the body. rcutis Biotherapeutics Inc. reported positive topline data from its Phase II clinical trial evaluating ARQ-154 (topical roflumilast foam) as a potential treatment for seborrheic dermatitis. Acrutis Biotherapeutics has initiated a Phase III clinical trial to treat Seborrheic Dermatitis.
This segment of the report provides insights about the different Seborrhea drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 5+ key companies which are developing the therapies for Seborrhea. The companies which have their Seborrhea drug candidates in the most advanced stage, i.e. Phase III include, Acrutis Biotherapeutics.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Seborrhea therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Seborrhea drugs.
Current Treatment Scenario and Emerging Therapies:
This product will be delivered within 2 business days.
Geography Covered
- Global coverage
Seborrhea Understanding
Seborrhea: Overview
Seborrheic dermatitis is a common skin disease that causes an itchy rash with flaky scales. It causes redness on light skin and light patches on darker skin. It's also called dandruff, cradle cap, seborrhea, seborrheic eczema, and seborrheic psoriasis. Seborrhea often affects the scalp. Other sites include the face, ears, eyebrows and eyelids, umbilicus, and genitalia. Primary seborrhea is inherited and Secondary seborrhea is more common; however the exact cause cannot always be determined.It is likely that a number of factors, such as hormones and stress, can cause it. A yeast-like organism plays an important role. Infants may get seborrhea. Seborrhea also affects adults and elderly persons, and is more common in men than in women. Seborrhea occurs more frequently in persons with oily skin. Medical history and the complete examination of the skin may help in the diagnosis. Seborrheic dermatitis will sometimes clear up by itself. But often, it's a lifelong issue that clears and flares.
"Seborrhea - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Seborrhea pipeline landscape is provided which includes the disease overview and Seborrhea treatment guidelines. The assessment part of the report embraces, in depth Seborrhea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Seborrhea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Seborrhea R&D. The therapies under development are focused on novel approaches to treat/improve Seborrhea.
Seborrhea Emerging Drugs Chapters
This segment of the Seborrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Seborrhea Emerging Drugs
ARQ-154: Acrutis Biotherapeutics
Roflumilast foam is a once-daily topical foam formulation of a highly potent and selective PDE4 inhibitor that Arcutis is developing particularly to treat inflammatory dermatoses in hair-bearing areas of the body such as the scalp, although it is usable in all areas of the body. rcutis Biotherapeutics Inc. reported positive topline data from its Phase II clinical trial evaluating ARQ-154 (topical roflumilast foam) as a potential treatment for seborrheic dermatitis. Acrutis Biotherapeutics has initiated a Phase III clinical trial to treat Seborrheic Dermatitis.
Seborrhea: Therapeutic Assessment
This segment of the report provides insights about the different Seborrhea drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Seborrhea
There are approx. 5+ key companies which are developing the therapies for Seborrhea. The companies which have their Seborrhea drug candidates in the most advanced stage, i.e. Phase III include, Acrutis Biotherapeutics.
Phases
This report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Seborrhea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Seborrhea: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Seborrhea therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Seborrhea drugs.
Seborrhea Report Insights
- Seborrhea Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Seborrhea Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Seborrhea drugs?
- How many Seborrhea drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Seborrhea?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Seborrhea therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Seborrhea and their status?
- What are the key designations that have been granted to the emerging drugs?
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive Summary
Seborrhea: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
ARQ-154: Acrutis Biotherapeutics
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Omiganan: Cutanea Life Sciences
- Product Description
- Research and Development
- Product Development Activities
Preclinical stage products
- Comparative Analysis
MSB-7154: MatriSys Bio
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Seborrhea Key Companies
Seborrhea Key Products
Seborrhea- Unmet Needs
Seborrhea- Market Drivers and Barriers
Seborrhea- Future Perspectives and Conclusion
Seborrhea Analyst Views
Seborrhea Key Companies
AppendixList of Tables
Table 1 Total Products for Seborrhea
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Seborrhea
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Cutanea Life Sciences
- Acrutis Biotherapeutics
- DermBiont
- Amorepacific
- MatriSys Bio
